• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

The path to faster visual recovery following glaucoma surgery

Digital EditionOphthalmology Times: September 15, 2021
Volume 46
Issue 15

Speed the return to baseline visual acuity—and make your patients happy.

A postoperative look at a Xen eye at 1 day, 1 week, and 1 month. (Images courtesy of Inder Paul Singh, MD)

Special to Ophthalmology Times®

The marvel of micro invasive glaucoma surgeries (MIGS)—and the reason we push them earlier in the disease course—is their safety and the predictable postoperative recovery. In the past, we had fewer options, most of which were more invasive.

As a result, we had to delay surgery for years while patients suffered the discomfort, inconvenience, and expense of multiple medications, until finally those medications were no longer enough and surgery was unavoidable.

Now we can skip years of suffering and better manage glaucoma by making MIGS part of the treatment equation.

Related: MIGS helping to personalize glaucoma surgery options

Historically, we were hesitant to go into the subconjunctival pathway with trabeculectomy or tube shunt because of the often slow and variable nature of visual recovery and complex postoperative management.

Instead, we waited until glaucoma progressed and the target pressure was aggressively low, often near the 10 to 12 mm Hg range.

Thankfully, with the options available today, we no longer need to wait so long to perform subconjunctival surgery for patients who need it, and with this earlier intervention, we have a better chance of achieving target IOPs because they are not so aggressively low.

Visual recovery and conventional pathway MIGS

With conventional pathway MIGS, such as stenting (iStent; Glaukos, Hydrus; Ivantis), viscodilating (iTrack; Nova Eye Medical, OMNI; Sight Sciences), stripping (Kahook Dual Blade goniotomy; New World Medical), cutting/GATT (OMNI), and others, visual recovery is generally not a major concern.

Pressurizing the eye intraoperatively usually prevents intraoperative and postoperative hyphema, although if it does still occur, it usually clears up in a short period of time.

The mechanisms that make visual recovery so seamless for conventional pathway MIGS are also the reason they are not always the best option:

The episcleral venous pressure is a floor we cannot cross, so it is hard to reach target pressures below the low to mid-teens.

Related: Patient glaucoma management focuses on pivotal studies

This floor, however, also means we do not get hypotony or flat chambers, which are often the cause of postoperative vision issues. Unfortunately, some of our patients need those lower target pressures.

We also do not know where the resistance to outflow is located in our patients with glaucoma; in some, the distal channels are also collapsed or atrophied. In these cases, we are not able to achieve the IOP control we need through the conventional outflow system.

We need to turn to a subconjunctival procedure to bypass the conventional pathway.

Vision after trabeculectomy or tube shunt surgery

Common causes of postoperative visual acuity changes are hypotony, choroidals, maculopathy, and ocular surface problems.

With trabeculectomy and tube shunt, all of these problems are possible, so it is difficult to gauge how long visual recovery will take with each patient.

Depending on how flat the chamber becomes and the position of the iris lens diaphragm complex, a return to baseline vision may take 1 week to 1 month or even longer.

Related: Restoring vision in glaucoma: more than meets the eye

A nonvalve tube might open up in a month and a half or even earlier when the suture dissolves, and that sudden change in IOP can cause a sudden shift in chamber depth and thus a change in vision.

In addition, postoperative drops can prolong recovery by destabilizing the ocular surface.1

In the case of weeks or months of recovery, patients are generally not happy with their vision. IOP can be unstable, so they require multiple office visits, and they often call the office with questions about vision problems and irritation from eye drop medications.

The recovery process may still be going on when it’s time for the patient to schedule surgery on the fellow eye, which can make them reluctant to do so.

As an experienced glaucoma specialist, I still marvel at the high potential for variability of each step for a trabeculectomy.

Related: Study: Lower IOP, medication burden in OAG patients

I use various techniques to manage outcomes by controlling the size, thickness, and shape of the flap; titrating the flow by suture placement and tension; and trying to aggressively bring down the IOP yet prevent chambers from flattening postoperatively.

It takes time to build that comfort and skill set, and not all patients have access to surgeons who have completed 1000-plus trabeculectomy procedures.2

For these and a variety of additional reasons, a less invasive and more predictable subconjunctival procedure is needed to allow access for more patients than traditional surgeries.

Faster visual recovery from subconjunctival MIGS
When we want to reach a lower pressure, avoid being beholden to conventional pathways where levels and locations of resistance can be uncertain, and follow a more predictable visual recovery than we get with traditional subconjunctival procedures; subconjunctival MIGS can deliver the benefits with few limitations.

The Xen Gel Stent (Allergan) uses the same bypass mechanism as trabeculectomy, but the only outflow created is a 45 μ lumen, rather than a larger, less consistent hole in the sclera with a variable flap.

Related: Micro-bypass stent implant during cataract surgery: lower IOP, fewer medications

With less structural deformation of the sclera, there is less chance of flat chambers postoperatively.

Even if numerical hypotony occurs, the chambers do not flatten as much because they retain greater structural integrity.

There is less concern that deformation of the eye will shift the iris lens diaphragm and cause a myopic shift or, in a pseudophakic patient, move or decenter a toric lens.

Based on the approval trial, Xen has demonstrated a high safety profile with few complications.3

The less invasive nature of Xen means the eye remains stable, with less inflammation in the anterior chamber and conjunctiva, often because there is no peripheral iridotomy, and if implanting from an external approach, intraoperative flattening of the anterior chamber is rare.


Since flow occurs through a single point around 5 mm posterior to the limbus, rather than in multiple directions closer to the limbus as in a trabeculectomy, the bleb forms more posteriorly and often with a lower profile, resulting in a quieter bleb and shorter-duration steroid use after surgery.

With fewer steroids and thus fewer topical preservatives, the ocular surface tends not to experience less disruption and resulting postoperative vision fluctuation.

Xen has also been shown to cause less endothelial cell loss than trabeculectomy, which could be an issue as patients get older and have other corneal risk factors.4

Although postoperative bleb needling is sometimes needed, my postoperative bleb needling rates have dropped significantly (now less than 10%) with changes in technique, intraoperative confirmation of a freely mobile stent, and use of an intraoperative needling if resistance is found.

If needling is required, it is a different type of intervention than a trabeculectomy needling. We do not see a sudden drop in IOP, so there is less change in chamber depth that could affect visual recovery.

Related: Glaucoma + nutrition: why what you eat matters

In the end, Xen reaches similarly low pressures as traditional subconjunctival surgeries with a predictable postoperative course, resulting in fewer visits (1 week and 1 month) and calls to my practice.5

Because of the high safety profile and rapid visual recovery, I have now offered Xen to patients who are refractory to drops despite their level of glaucoma severity.

For instance, a patient with mild or moderate open-angle glaucoma who is taking 4 classes of medications, has a history of a previous MIGS, has stable IOP and visual folds, but is not compliant with drops would not typically have been a subconjunctival bypass candidate in the past, but this patient is now a perfect candidate for a Xen. Welcome to the interventional glaucoma mind-set.

About the author

Inder Paul Singh, MD
e: ipsingh@amazingeye.com
Inder Paul Singh, MD, is president of The Eye Centers of Racine and Kenosha, Wisconsin. He is a consultant to Alcon, Allergan, Bausch + Lomb, Ellex, Glaukos, Iantech, New World Medical, Omeros, Shire, and Zeiss.



1. Francis BA, Hong B, Winarko J, Kawji S, Dustin L, Chopra V. Vision loss and recovery after trabeculectomy: risk and associated risk factors. Arch Ophthalmol. 2011;129(8):1011-1017. doi:10.1001/archophthalmol.2011.182

2. Birchall W, Bedggood A, Wells AP. Do scleral flap dimensions influence reliability of intraocular pressure control in experimental trabeculectomy? Eye (Lond). 2007;21(3):402-407. doi:10.1038/sj.eye.6702253

3. Reitsamer H, Vera V, Ruben S, et al. Three-year effectiveness and safety of the Xen gel stent as a solo procedure or in combination with phacoemulsification in open-angle glaucoma: a multicentre study. Acta Ophthalmol. Published online May 10, 2021. doi:10.1111/aos.14886

4. Olgun A, Duzgun E, Yildiz AM, Atmaca F, Yildiz AA, Sendul SY. Xen Gel Stent versus trabeculectomy: short-term effects on corneal endothelial cells. Eur J Ophthalmol. 2021;31(2):346-353. doi:10.1177/1120672120924339

5. Marcos Parra MT, Salinas López JA, López Grau NS, Ceausescu AM, Pérez Santonja JJ. Xen implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2019;257(8):1741-1750. doi:10.1007/s00417-019-04341-y

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.